

RECEIVED  
CENTRAL FAX CENTERFACSIMILE COVER SHEET

AUG 26 2004

*GlaxoSmithKline*  
Corporate Intellectual Property  
5 Moore Drive, Research Triangle Park  
Durham, NC 27709

To: Examiner DAVID LUKTON  
Company/Division: USPTO  
Phone: 571/272-0952  
Fax: 703/872-9306

From: J. Michael Strickland  
Company/Division: *GlaxoSmithKline*  
Phone: 919-483-9024  
Fax: 919-483-7988

Date: August 26, 2004  
Pages to follow: 19

*This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable federal or state law. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited.*

Subject: Combined Amendment & Petition for Ext. of Time Under 37 CFR 1.136(a) & Amendment

RE: Response to Office Action of April 29, 2004  
Applicant of: ARMOUR, Duncan Robert, et. al.  
U.S. Serial No.: 09/868,395 Filed: 09/06/2001  
Title: COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES  
Art Unit: 1653  
Attorney Docket No.: PG3612USW

Attached:

1. Certificate of Transmission (37 CFR 1.8(a))
2. Combined Amendment & Petition for Extension of Time Under 37 CFR 1.136(a)
3. Amendment



**COMBINED AMENDMENT & PETITION FOR EXTENSION OF  
TIME UNDER 37 CFR 1.136(a) (Large Entity)**

Docket No.

PG3612USW

RECEIVED

CENTRAL FAX CENTER

In Re Application Of: **ARMOUR, Duncan Robert, et. al.**

AUG 26 2004

Application No. 09/868,395	Filing Date 09/06/2001	Examiner David Lukton	Customer No. 23347	Group Art Unit 1653	Confirmation No. 8883
-------------------------------	---------------------------	--------------------------	-----------------------	------------------------	--------------------------

Invention: **COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES**COMMISSIONER FOR PATENTS:

This is a combined amendment and petition under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the Office Action of April 29, 2004 in the above-identified application.

Date

The requested extension is as follows (check time period desired):

☒ One month    ☐ Two months    ☐ Three months    ☐ Four months    ☐ Five months
from: July 29, 2004

Date

until:

August 29, 2004

Date

The fee for the amendment and extension of time has been calculated as shown below:

## CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	20 -	27 =	0	x \$18.00	\$0.00
INDEP. CLAIMS	5 -	5 =	0	x \$86.00	\$0.00
FEE FOR AMENDMENT					\$0.00
FEE FOR EXTENSION OF TIME					\$110.00
TOTAL FEE FOR AMENDMENT AND EXTENSION OF TIME					\$110.00

P26LARGE/REV04


**COMBINED AMENDMENT & PETITION FOR EXTENSION OF  
TIME UNDER 37 CFR 1.136(a) (Large Entity)**Docket No.  
PG3612USWRECEIVED  
CENTRAL FAX CENTER

AUG 26 2004

The fee for the amendment and extension of time is to be paid as follows:

- ☐ A check in the amount of \_\_\_\_\_ for the amendment and extension of time is enclosed.
- ☒ Please charge Deposit Account No. 07-1392 in the amount of \$110.00
- ☒ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☐ If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

  
Signature

J. Michael Strickland  
Registration No.: 47,115  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Tel.: 919/483-9024 Fax: 919/483-7988

CC:

Dated: August 26, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] o.  
(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

P28LARGE/REV04